Effect of topical diclofenac on postoperative photorefractive keratectomy pain: a randomized, controlled trial

2014 ◽  
Vol 42 (9) ◽  
pp. 810-814 ◽  
Author(s):  
Alireza Eslampoor ◽  
Asieh Ehsaei ◽  
Mojtaba Abrishami
Keyword(s):  
Randomized Controlled Trial ◽  
Controlled Trial ◽  
Photorefractive Keratectomy ◽  
Randomized Controlled ◽  
Topical Diclofenac

A Randomized Controlled Trial Comparing Dexamethasone with Loteprednol Etabonate on Postoperative Photorefractive Keratectomy

2015 ◽  
Vol 31 (3) ◽  
pp. 165-168 ◽  
Author(s):  
Onsiri Thanathanee ◽  
Phornrak Sriphon ◽  
Orapin Anutarapongpan ◽  
Raweewan Athikulwongse ◽  
Prakairat Thongphiew ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Controlled Trial ◽  
Photorefractive Keratectomy ◽  
Loteprednol Etabonate ◽  
Randomized Controlled

scholarly journals Effectiveness And Safety of Acupotomy For Knee Osteoarthritis: Study Protocol For A Randomized Controlled Trial

2021 ◽  
Author(s):  
Wu-Zhong Cheng ◽  
Tian-Li Li ◽  
Ren Guo ◽  
Ping Chen ◽  
Wei-Shuai Du ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Knee Osteoarthritis ◽  
Controlled Trial ◽  
Joint Fluid ◽  
Clinical Trial Registry ◽  
Randomized Controlled ◽  
Group A ◽  
And Function ◽  
Group D ◽  
Topical Diclofenac

Abstract Background: Knee osteoarthritis (KOA) is one of the most common musculoskeletal disorders. Acupotomy may be effective for KOA, but evidence is limited. The aim of this trial is to determine the effectiveness and safety of acupotomy for KOA.Methods/design: This is a parallel-group, assessor-blinded randomized controlled trial. Two hundred patients with KOA will be recruited and randomly assigned to two groups (group A or group D) in a 1:1 ratio. Patients in group A will receive acupotomy and topical diclofenac diethylamine for 4 weeks, while patients in group D will receive topical diclofenac diethylamine alone for 4 weeks. The primary outcome will be the response rate—the proportion of patients who achieve the minimal clinically important improvement in pain and function at week 4 compared with baseline. Secondary outcomes will include pain, function, quality of life, the use of rescue medicine (loxoprofen sodium) and adverse events at weeks 4, 8 and 24 after randomization. Besides, joint fluid and serum will be collected to assess the level of inflammatory cytokines, like TNF-α, IL-1β and MMP-3.Discussion: This study will contribute to a better understanding of the effectiveness and safety of acupotomy in combination with topical nonsteroidal anti-inflammatory drugs. Results of the study will be of great importance for the guidelines of clinical therapy.Trial registration: Chinese Clinical Trial Registry (No. ChiCTR2100043005, http://www.chictr.org.cn/showproj.aspx?proj=121348) Registered on 4 February 2021.

scholarly journals Effectiveness and safety of acupotomy for knee osteoarthritis: study protocol for a randomized controlled trial

Trials ◽  
2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Shu-Ming Li ◽  
Tian-Li Li ◽  
Ren Guo ◽  
Ping Chen ◽  
Wei-Shuai Du ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Knee Osteoarthritis ◽  
Controlled Trial ◽  
Joint Fluid ◽  
Clinical Trial Registry ◽  
Randomized Controlled ◽  
Group A ◽  
And Function ◽  
Group D ◽  
Topical Diclofenac

Abstract Background Knee osteoarthritis (KOA) is one of the most common musculoskeletal disorders. Acupotomy may be effective for KOA, but the evidence is limited. This trial aims to determine the effectiveness and safety of acupotomy for KOA. Methods/design This is a parallel-group, assessor-blinded randomized controlled trial. Two hundred patients with KOA will be recruited and randomly assigned to two groups (group A or group D) in a 1:1 ratio. Patients in group A will receive acupotomy and topical diclofenac diethylamine for 4 weeks, while patients in group D will receive topical diclofenac diethylamine alone for 4 weeks. The primary outcome will be the response rate—the proportion of patients who achieve the minimal clinically important improvement in pain and function at week 4 compared with baseline. Secondary outcomes will include pain, function, quality of life, the use of rescue medicine (loxoprofen sodium), and adverse events at weeks 4, 8, and 24 after randomization. Besides, joint fluid and serum will be collected to assess the level of inflammatory cytokines, like TNF-α, IL-1β, and MMP-3. Discussion This study will contribute to a better understanding of the effectiveness and safety of acupotomy in combination with topical nonsteroidal anti-inflammatory drugs. If the hypothesis is confirmed, acupotomy may be recommended as adjunctive therapy for patients with KOA. Results of the study will be of great importance for the guidelines of clinical therapy. Trial registration Chinese Clinical Trial Registry ChiCTR2100043005 Registered on 4 February 2021.

Pregabalin and Gabapentin for Post-Photorefractive Keratectomy Pain: A Randomized Controlled Trial

2012 ◽  
Vol 22 (7_suppl) ◽  
pp. 106-113 ◽  
Author(s):  
Mohammad Pakravan ◽  
Maryam Roshani ◽  
Shahin Yazdani ◽  
Amir Faramazi ◽  
Mehdi Yaseri
Keyword(s):  
Randomized Controlled Trial ◽  
Controlled Trial ◽  
Photorefractive Keratectomy ◽  
Randomized Controlled

Treatment Fidelity Procedures for an Aphasia Intervention Within a Randomized Controlled Trial: Design, Feasibility, and Results

2020 ◽  
Vol 29 (1S) ◽  
pp. 412-424
Author(s):  
Elissa L. Conlon ◽  
Emily J. Braun ◽  
Edna M. Babbitt ◽  
Leora R. Cherney
Keyword(s):  
Randomized Controlled Trial ◽  
Controlled Trial ◽  
Treatment Protocol ◽  
Treatment Fidelity ◽  
Protocol Adherence ◽  
Study Condition ◽  
Randomized Controlled ◽  
Aphasia Therapy ◽  
Percent Accuracy ◽  
Over Time

Purpose This study reports on the treatment fidelity procedures implemented during a 5-year randomized controlled trial comparing intensive and distributed comprehensive aphasia therapy. Specifically, the results of 1 treatment, verb network strengthening treatment (VNeST), are examined. Method Eight participants were recruited for each of 7 consecutive cohorts for a total of 56 participants. Participants completed 60 hr of aphasia therapy, including 15 hr of VNeST. Two experienced speech-language pathologists delivered the treatment. To promote treatment fidelity, the study team developed a detailed manual of procedures and fidelity checklists, completed role plays to standardize treatment administration, and video-recorded all treatment sessions for review. To assess protocol adherence during treatment delivery, trained research assistants not involved in the treatment reviewed video recordings of a subset of randomly selected VNeST treatment sessions and completed the fidelity checklists. This process was completed for 32 participants representing 2 early cohorts and 2 later cohorts, which allowed for measurement of protocol adherence over time. Percent accuracy of protocol adherence was calculated across clinicians, cohorts, and study condition (intensive vs. distributed therapy). Results The fidelity procedures were sufficient to promote and verify a high level of adherence to the treatment protocol across clinicians, cohorts, and study condition. Conclusion Treatment fidelity strategies and monitoring are feasible when incorporated into the study design. Treatment fidelity monitoring should be completed at regular intervals during the course of a study to ensure that high levels of protocol adherence are maintained over time and across conditions.

Sign in / Sign up

Export Citation Format

Share Document